Methods for detecting atrial fibrillation and related conditions

• US 20110097710A1
• Filed: 10/25/2005
• Published: 04/28/2011
• Est. Priority Date: 10/26/2004
• Status: Abandoned Application

• Current Assignee: The General Hospital Corporation (Mass General Brigham, Inc.)
• Original Assignee: The General Hospital Corporation (Mass General Brigham, Inc.)
• Inventors: Low, Adrian F., Ellinor, Patrick T., Macrae, Calum A.
• Application Number:
  US11/666,574
• Publication Number:
  US 20110097710A1
• Time in Patent Office: Days
• US Class Current: 435/6.17
• CPC Class Codes: A61B 5/00 Measuring for diagnostic purposes radiation diagnosis A61B6/00; diagnosis by ultrasonic, sonic or infrasonic waves A61B8/00; Identification of persons
• CPC Class Codes: A61B 5/361 Detecting fibrillation
• CPC Class Codes: Y10T 436/143333 Saccharide [e.g., DNA, etc.]

Abstract

Methods for detecting disorders associated with atrial fibrillation, and, thus, at risk for stroke and/or heart failure) in a subject based on a monitoring plasma levels of apelin are provided. Diagnostic compositions for the detection of such disorders are additionally provided.

Claims

1. A method of detecting a disorder associated with a cardiac arrhythmia in a subject having said disorder comprising measuring the amount of an apelin polypeptide, or a fragment thereof, in the plasma of the subject, and determining that the amount is reduced in comparison to that of a control subject, thereby detecting said disorder.

2. The method of claim 1, wherein the disorder is atrial fibrillation.

3. The method of claim 2, wherein the atrial fibrillation is lone atrial fibrillation.

4. The method of claim 3, wherein the apelin polypeptide is apelin-12.

5. The method of claim 1, wherein the measuring comprises contacting the plasma or a preparation thereof with an immunological agent the binds with specificity to the apelin polypeptide or fragment thereof.

17. A kit for detecting a disorder associated with cardiac arrhythmia comprising an immunological agent that binds with specificity to an apelin polypeptide or a fragment thereof and instructions for use according to claim 1.

18. The kit of claim 17, further comprising a means for quantitating the amount of the apelin polypeptide, or fragment thereof, in a plasma sample or preparation thereof obtained from a subject having a cardiac arrhythmia and for determining that the amount is reduced in comparison to a control sample.

6. A method of detecting a disorder associated with a cardiac arrhythmia in a subject having said disorder comprising measuring the amount of an apelin nucleotide sequence in the circulating cells or plasma of the subject, and determining that the amount is reduced in comparison to that of a control subject, thereby detecting said disorder.

7. The method of claim 6, wherein the disorder is atrial fibrillation.

8. The method of claim 6, wherein the apelin polypeptide is apelin-12.

9. The method of claim 6, wherein the measuring comprises contacting the circulating cells or plasma or a preparation thereof with at least one nucleic acid probe having a nucleic acid sequence complementary to the nucleic acid sequence of apelin or an isoform thereof.

10. The method of claim 9, wherein the nucleic acid sequence of apelin or an isoform thereof is a ribonucleic acid (RNA) sequence.

19. A kit for detecting a disorder associated with cardiac arrhythmia comprising a means for determining the amount of expression of the apelin polypeptide or a fragment thereof and instructions for use according to claim 6.

20. The kit of claim 19, wherein the means comprises at least one nucleic acid probe having a nucleic acid sequence complementary to the nucleic acid sequence of an apelin or an isoform thereof.

21. The kit of claim 17 or 10, wherein the disorder is atrial fibrillation.

23. The kit of claim 19, wherein the disorder is atrial fibrillation.

11. A method of identifying a subject having or at risk of having atrial fibrillation comprising measuring the amount of an apelin polypeptide, or a fragment thereof, in the circulating cells or plasma or a preparation thereof of the subject, and determining that the amount is reduced in comparison to that of a control subject, thereby identifying the subject having or at risk of having atrial fibrillation.

12. The method of claim 11, wherein the atrial fibrillation is lone atrial fibrillation.

13. The method of claim 11, wherein the apelin polypeptide is apelin-12.

14. The method of claim 11, wherein the measuring comprises contacting the plasma or a preparation thereof with an immunological agent that binds with specificity to the apelin polypeptide or fragment thereof.

15. The method of claim 11, wherein the measuring comprises determining the amount of expression of the apelin polypeptide or a fragment thereof.

16. The method of claim 15, wherein determining the amount of expression comprises contacting the circulating cells or plasma or a preparation thereof with at least one nucleic acid probe having a nucleic acid sequence complementary to apelin or an isoform thereof.

22. An article of manufacture for diagnosing a predisposition for atrial fibrillation in a subject comprising packaging material, a diagnostic kit, and instructions with the packaging material, wherein the diagnostic kit comprises an immunological agent that binds with specificity to the apelin polypeptide, or a fragment thereof, to form a bound complex and a means for measuring the quantity of bound complexes in a biological sample or a preparation thereof of a subject, wherein the quantity of bound complex as compared to a normal control is indicative for a predisposition for atrial fibrillation, and wherein the instructions indicate that the diagnostic kit can be used to diagnose a predisposition for atrial fibrillation in the subject.